Thromboxane biosynthesis and antagonism in humans.
Despite the evanescence of TXA2 in biological fluids, recent developments promise to considerably enhance our insight into the role of this molecule in vivo. Clinical trials already suggest that it plays an important role in certain human diseases, such as unstable angina. Combined administration of TX antagonists and TX synthase inhibitors offers a theoretical advantage over aspirin which may ultimately justify their place in the therapy of vascular disease in humans.